Tags

Type your tag names separated by a space and hit enter

Serum selenium and selenoprotein-P levels in autoimmune thyroid diseases patients in a select center: a transversal study.
Arch Endocrinol Metab 2017; 61(6):600-607AE

Abstract

OBJECTIVE

Selenium (Se) supplementation has been used to help prevent the progression of Graves' ophthalmopathy (GO) and autoimmune thyroid diseases (AITD) patients. We investigated Se serum and selenoprotein P (SePP) levels in Graves' disease (GD) with and without GO, Hashimoto's thyroiditis (HT) patients and in 27 control individuals (C).

SUBJECTS AND METHODS

We studied 54 female and 19 male patients: 19 with GD without GO, 21 GD with GO, 14 with HT and 19 with HT+LT4. Se values were measured using graphite furnace atomic absorption spectrophotometry. Serum SePP levels were measured by ELISA.

RESULTS

Median Se levels were similar among all groups; GD patients: 54.2 (46.5-61.1 μg/L), GO: 53.6 (43.5-60.0 μg/L), HT: 51.9 (44.6-58.5 μg/L), HT+LT4 54.4 (44-63.4) and C group patients: 56.0 (52.4-61.5 μg/L); P = 0.48. However, serum SePP was lower in GO patients: 0.30 (0.15-1.05 μg/mL) and in HT patients: 0.35 (0.2-1.17 μg/mL) compared to C group patients: 1.00 (0.564.21 μg/mL) as well as to GD patients: 1.19 (0.62-2.5 μg/mL) and HT+LT4 patients: 0.7 (0,25-1.95); P = 0.002. Linear regression analysis showed a significant relationship between SePP and TPOAb values (r = 0.445, R2 = 0.293; P < 0.0001). Multiple regression analysis found no independent variables related to Se or SePP.

CONCLUSION

A serum Se concentration was lower than in some other countries, but not significantly among AITD patients. The low serum SePP levels in GO and HT patients seems to express inflammatory reactions with a subsequent increase in Se-dependent protein consumption remains unclear.

Authors+Show Affiliations

Endocrinología, Hospital do Servidor Público Estadual (IAMSPE), São Paulo, SP Brasil.Endocrinología, Hospital do Servidor Público Estadual (IAMSPE), São Paulo, SP Brasil.Endocrinología, Hospital do Servidor Público Estadual (IAMSPE), São Paulo, SP Brasil.Endocrinología, Hospital do Servidor Público Estadual (IAMSPE), São Paulo, SP Brasil.Endocrinología, Hospital do Servidor Público Estadual (IAMSPE), São Paulo, SP Brasil.Endocrinología, Hospital do Servidor Público Estadual (IAMSPE), São Paulo, SP Brasil.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29412385

Citation

Federige, Marco Aurélio Ferreira, et al. "Serum Selenium and selenoprotein-P Levels in Autoimmune Thyroid Diseases Patients in a Select Center: a Transversal Study." Archives of Endocrinology and Metabolism, vol. 61, no. 6, 2017, pp. 600-607.
Federige MAF, Romaldini JH, Miklos ABPP, et al. Serum selenium and selenoprotein-P levels in autoimmune thyroid diseases patients in a select center: a transversal study. Arch Endocrinol Metab. 2017;61(6):600-607.
Federige, M. A. F., Romaldini, J. H., Miklos, A. B. P. P., Koike, M. K., Takei, K., & Portes, E. S. (2017). Serum selenium and selenoprotein-P levels in autoimmune thyroid diseases patients in a select center: a transversal study. Archives of Endocrinology and Metabolism, 61(6), pp. 600-607. doi:10.1590/2359-3997000000309.
Federige MAF, et al. Serum Selenium and selenoprotein-P Levels in Autoimmune Thyroid Diseases Patients in a Select Center: a Transversal Study. Arch Endocrinol Metab. 2017;61(6):600-607. PubMed PMID: 29412385.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum selenium and selenoprotein-P levels in autoimmune thyroid diseases patients in a select center: a transversal study. AU - Federige,Marco Aurélio Ferreira, AU - Romaldini,João Hamilton, AU - Miklos,Ana Beatriz Pinotti Pedro, AU - Koike,Marcia Kiyomi, AU - Takei,Kioko, AU - Portes,Evandro de Souza, PY - 2017/03/13/received PY - 2017/07/31/accepted PY - 2018/2/8/entrez PY - 2018/2/8/pubmed PY - 2018/4/26/medline SP - 600 EP - 607 JF - Archives of endocrinology and metabolism JO - Arch Endocrinol Metab VL - 61 IS - 6 N2 - OBJECTIVE: Selenium (Se) supplementation has been used to help prevent the progression of Graves' ophthalmopathy (GO) and autoimmune thyroid diseases (AITD) patients. We investigated Se serum and selenoprotein P (SePP) levels in Graves' disease (GD) with and without GO, Hashimoto's thyroiditis (HT) patients and in 27 control individuals (C). SUBJECTS AND METHODS: We studied 54 female and 19 male patients: 19 with GD without GO, 21 GD with GO, 14 with HT and 19 with HT+LT4. Se values were measured using graphite furnace atomic absorption spectrophotometry. Serum SePP levels were measured by ELISA. RESULTS: Median Se levels were similar among all groups; GD patients: 54.2 (46.5-61.1 μg/L), GO: 53.6 (43.5-60.0 μg/L), HT: 51.9 (44.6-58.5 μg/L), HT+LT4 54.4 (44-63.4) and C group patients: 56.0 (52.4-61.5 μg/L); P = 0.48. However, serum SePP was lower in GO patients: 0.30 (0.15-1.05 μg/mL) and in HT patients: 0.35 (0.2-1.17 μg/mL) compared to C group patients: 1.00 (0.564.21 μg/mL) as well as to GD patients: 1.19 (0.62-2.5 μg/mL) and HT+LT4 patients: 0.7 (0,25-1.95); P = 0.002. Linear regression analysis showed a significant relationship between SePP and TPOAb values (r = 0.445, R2 = 0.293; P < 0.0001). Multiple regression analysis found no independent variables related to Se or SePP. CONCLUSION: A serum Se concentration was lower than in some other countries, but not significantly among AITD patients. The low serum SePP levels in GO and HT patients seems to express inflammatory reactions with a subsequent increase in Se-dependent protein consumption remains unclear. SN - 2359-4292 UR - https://www.unboundmedicine.com/medline/citation/29412385/Serum_selenium_and_selenoprotein_P_levels_in_autoimmune_thyroid_diseases_patients_in_a_select_center:_a_transversal_study_ L2 - http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S2359-39972017000600600&amp;lng=en&amp;nrm=iso&amp;tlng=en DB - PRIME DP - Unbound Medicine ER -